摘要
急性髓系白血病(acute myeloid leukemia, AML)是成人中最常见的白血病,其预后差、生存期短,具有高度异质性和显著的细胞遗传学特征。近年来随着分子靶向及细胞生物学的发展,在传统化疗方案基础上出现多种新方法可用于该疾病治疗。本综述着重讨论了针对疾病特有的细胞遗传学及复发性基因改变的分子靶向药物治疗(如FLT3抑制剂、IDH抑制剂、BCL-2抑制剂、Hedgehog通路抑制剂等)、新兴免疫疗法(如CAR-T细胞治疗等),有望进一步扩大AML治疗选择并提高患者生存率。
Acute myeloid leukemia (AML) is the most common leukemia in adults, characterized by poor prognosis, short survival, high heterogeneity and significant cytogenetic characteristics. In recent years, with the development of molecular targeting and cell biology, many new methods have ap-peared on the basis of traditional chemotherapy for the treatment of this disease. This review fo-cuses on molecular targeted drug therapies targeting disease-specific cytogenetics and recurrent gene changes (e.g., FLT3 inhibitors, IDH inhibitors, BCL-2 inhibitors, Hedgehog pathway inhibitors, etc.), emerging immunotherapies (e.g., CAR T cell therapy). It is expected to further expand treat-ment options for AML and improve patient survival.
出处
《临床医学进展》
2023年第3期3911-3918,共8页
Advances in Clinical Medicine
